Investors & Media

Sunesis is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs. We believe the quality and breadth of our product candidate pipeline, platform technology, strategic collaborations and scientific team will enable us to become a fully integrated biopharmaceutical company with a diversified portfolio of novel therapeutics for major diseases.

1:48 PM ET - Jul 09, 2007
Price	$3.56
Change	$0.02
Day Range	$3.52 - $3.56
Volume	14,500

Market data powered by TurboFeed.
Delayed at least 15 minutes.

Get a detailed stock quote

Annual Report and Form 10-K
(2005, PDF 698k)

Discovering the Sunesis Difference
(May 2007, PDF 675k)

Latest News

July 3, 2007

Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

June 21, 2007

Sunesis Pharmaceuticals to Present at the Jefferies Healthcare Conference

June 11, 2007

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

June 8, 2007

Sunesis Pharmaceuticals to Present at Needham Biotechnology & Medical Technology Conference

Sunesis is an innovative biopharmaceutical company focused on therapeutics for oncology and other unmet medical needs.

Get general information about clinical studies, and learn about Sunesis investigational drugs currently in clinical trial.